Premium
Interleukin‐6 as an Early Chronic Inflammatory Marker in Polycystic Ovary Syndrome with Insulin Receptor Substrate‐2 Polymorphism
Author(s) -
Lin YueShan,
Tsai ShawJenq,
Lin MingWei,
Yang ChengTa,
Huang MeiFeng,
Wu MengHsing
Publication year - 2011
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/j.1600-0897.2011.01059.x
Subject(s) - polycystic ovary , medicine , endocrinology , metformin , genotyping , insulin resistance , insulin , population , polymorphism (computer science) , allele , genotype , biology , genetics , gene , environmental health
Citation Lin Y‐S, Tsai S‐J, Lin M‐W, Yang C‐T, Huang M‐F, Wu M‐H. Interleukin‐6 as an early chronic inflammatory marker in polycystic ovary syndrome with insulin receptor substrate‐2 polymorphism. Am J Reprod Immunol 2011; 66: 527–533 Problem Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disorder. This study was to evaluate whether insulin receptor substrate (IRS)‐2 Gly1057Asp polymorphism influences chronic inflammatory parameters in Taiwanese patients with PCOS. Method of study DNA was extracted from whole blood samples for genotyping and detection of IRS‐2 Gly1057Asp polymorphism in 129 PCOS women and 109 control women. Ninety‐seven PCOS women accepted metformin treatment for 3 months, and low‐grade chronic inflammatory markers were assessed. Results The levels of IL‐6 were significantly elevated in PCOS women compared with normal women. Among allelic variant of IRS‐2, concentrations of IL‐6 were greater in IRS‐2 homozygous Asp population. Treatment with metformin significantly reduced IL‐6, especially in PCOS patients with IRS‐2 homozygous Asp variant. Conclusion The results showed that IL‐6 may be an early low‐grade chronic inflammatory marker among PCOS patients with IRS‐2 polymorphism in Taiwanese population. This pharmacologic study in IRS‐2 polymorphism may provide more information for preventing long‐term complications in PCOS.